TrialNature communications2025

Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial.

Xiaohua Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.